« Back
Home /
GLPG1690

GLPG1690

Item no.	TMO-T4041-100mg
Manufacturer	TargetMol
CASRN	1628260-79-6
Amount	100mg
Category	Metabolism Cholesterol & Lipid Metabolism Reagents & Chemicals Molecules
Type	Molecules
Specific against	other
Citations	1.Desroy N., et al. Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic PulmoN/Ary Fibrosis. J Med Chem. 2017 May 11;60(9):3580-3590.
Smiles	CCc1nc2c(C)cc(cn2c1N(C)c1nc(c(s1)C#N)-c1ccc(F)cc1)N1CCN(CC(=O)N2CC(O)C2)CC1
ECLASS 5.1	32169090
ECLASS 6.1	32169090
ECLASS 8.0	32169090
ECLASS 9.0	32169090
ECLASS 10.0.1	32169090
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Alias	PDE inhibitor, GLPG1690
Available
Short Description	Ziritaxestat (GLPG1690), an autotaxin inhibitor, currently being evaluated in an exploratory phase 2 study in idiopathic pulmonary fibrosis patients.
Shipping	cool pack
Storage	-20°
Target names or alias	GLPG1690
Molecular Weight	588, 71
Pathway	Metabolism
Target	PDE

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 100mg

available

Delivery expected until 8/2/2024